A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

  • STATUS
    Recruiting
  • End date
    Jun 2, 2023
  • participants needed
    135
  • sponsor
    AbbVie
Updated on 11 August 2022
cancer
cyclophosphamide
tyrosine
cytarabine
rituximab
vincristine
decitabine
bone marrow procedure
etoposide
dexamethasone
azacitidine
venetoclax
primary cancer
solid tumour
solid neoplasm
topotecan

Summary

An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of venetoclax in pediatric and young adult participants with relapsed or refractory malignancies.

Details
Condition Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Neuroblastoma
Treatment Chemotherapy, venetoclax
Clinical Study IdentifierNCT03236857
SponsorAbbVie
Last Modified on11 August 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Participants must have relapsed or refractory cancer
Participants must have adequate hepatic and kidney function
Participants less than or equal to 16 years of age must have performance status of Lansky greater than or equal to 50% and participants greater than 16 years of age must have performance status of Karnofsky greater than or equal to 50%
Participants with solid tumors (with the exception of neuroblastoma) must have adequate bone marrow function in Part 1
For the fifth cohort during Part 2 Cohort Expansion, participants with solid tumors must have evidence of BCL-2 expression (except participants with TCF3-HLF ALL)

Exclusion Criteria

Participants with primary brain tumors or disease metastatic to the brain
Participants who have central nervous system (CNS) disease with cranial involvement that requires radiation
Participants who have received any of the following within the listed time frame, prior to the first dose of study drug
Inotuzumab ozogamicin or gemtuzumab ozogamicin within 30 days
Biologic agent (i.e., antibodies) for anti-neoplastic intent within 30 days or 5 half-lives whichever is shorter
CAR-T infusion or other cellular therapy within 30 days
Anticancer therapy including chemotherapy, radiation therapy, targeted small molecule agents, investigational agents within 14 days or 5 half-lives, whichever is shorter (Exceptions: Ph+ALL participants on Tyrosine Kinase Inhibitor (TKI) at Screening may enroll and remain on TKI therapy to control disease and TCF3-HLF ALL participants are allowed to have received chemotherapy within 14 days or 5 half-lives, whichever is shorter)
Steroid therapy for anti-neoplastic intent within 5 days (with the exception of TCF3-HLF ALL participants)
Requires ongoing hydroxyurea (hydroxyurea permitted up to first dose)
Participants who are less than 100 days post-transplant, or greater than or equal to
days post-transplant with active graft versus host disease (GVHD), or are
Participants who are less than 6 weeks post-131 I-metaiodobenzylguanidine (mIBG) therapy
receiving immunosuppressant therapy within 7 days prior to first dose of study
Participants who have received the following within 7 days prior to the first dose of study drug
drug
Strong and moderate Cytochrome P450 3A (CYP3A) inhibitors (Part 1 Dose Determination)
Strong and moderate CYP3A inducers (Part 1 Dose Determination and Part 2 Cohort Expansion)
Participants who have active, uncontrolled infections
Participants with malabsorption syndrome or any other condition that precludes enteral administration
Participants with recent positive test for SARS-CoV-2 (COVID-19) and no follow up test with negative result cannot be enrolled. Participants with contact to persons with COVID-19 and participants with signs and symptoms for COVID-19 infection must be tested before enrolling
Participants who have not recovered from clinically significant adverse
effect(s)/toxicity(s) of the previous therapy (Exception: Chemotherapy induced
side effects that are expected to return to baseline in TCF3-HLF ALL
participants)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note